1. Home
  2. Ãéá ôï ãéáôñü
  3. ÅðéäçìéïëïãéêÞ ÅðéôÞñçóç

ÅðéäçìéïëïãéêÞ ÅðéôÞñçóç ôïõ HIV/AIDS

Global map of the AIDS epidemic

Ç ðáãêüóìéá êáôÜóôáóç êáé ïé ôÜóåéò:
Áðü ôçí áñ÷Þ ôçò åðéäçìßáò, ó÷åäüí 80 åêáôïììýñéá Üíèñùðïé Ý÷ïõí ìïëõíèåß ìå ôïí éü HIV êáé ðåñßðïõ 40 åêáôïììýñéá Üíèñùðïé Ý÷ïõí ðåèÜíåé. ÓõíïëéêÜ, 36,7 åêáôïììýñéá [34 Ýùò 39,8 åêáô.] Üíèñùðïé æïýóáí ìå ôïí éü HIV ùò ôá ôÝëç ôïõ 2015. ÅêôéìÜôáé üôé 0,8% ôùí åíçëßêùí çëéêßáò 15-49 åôþí óå üëï ôïí êüóìï æïõí ìå ôïí éü HIV, áí êáé ôï âÜñïò ôçò åðéäçìßáò åîáêïëïõèåß íá ðïéêßëëåé óçìáíôéêÜ ìåôáîý ôùí ÷ùñþí êáé ôùí ðåñéï÷þí. Ç õðïóá÷Üñéá ÁöñéêÞ ðáñáìÝíåé ç ðåñéï÷Þ ðïõ åðçñåÜæåôáé ðéï óïâáñÜ, ìå ó÷åäüí 1 óôïõò 20 åíÞëéêåò íá æïõí ìå ôïí éü HIV êáé áíôéðñïóùðåýïõí ó÷åäüí ôï 70% ôùí áíèñþðùí ðïõ æïõí ìå ôïí éü HIV óå üëï ôïí êüóìï.

Global AIDS epidemic

HIV ëïéìþîåéò óôçí ÅëëÜäá áíÜ Ýôïò êáé áíÜ öýëï

Óýìöùíá ìå ôï ôåëåõôáßï äåëôßï åðéäçìéïëïãéêÞò åðéôÞñçóçò ôçò HIV Ëïßìùîçò ùò ôïí Ïêôþâñéï ôïõ 2015 äéáãíþóôçêáí óõíïëéêÜ óôçí ÅëëÜäá 15.109 ïñïèåôéêÜ Üôïìá (ôï 82,7% åßíáé Üíäñåò).

*Ï áñéèìüò ôïõ 2016 áöïñÜ ôéò êáôáãåãñáììÝíåò íÝåò äéáãíþóåéò Ýùò ôá ôÝëç Ïêôùâñßïõ 2016
Áðü ôï óýíïëï áõôþí ôùí áôüìùí, 3.923 Ý÷ïõí ìðåé óôï êëéíéêü óôÜäéï ôïõ AIDS êáé ðåñßðïõ 8.600 âñßóêïíôáé õðü áíôéñåôñïúêÞ èåñáðåßá.

Facts about HIV/AIDS in Greece:

  • 2.662 ïñïèåôéêïß ðÝèáíáí Ýùò ôþñá 2
  • 13.1333 Üôïìá ãíùñßæïõí üôé æïõí ìå ôïí éü HIV 2
  • 83% åßíáé Üíäñåò 2
  • 6,8% åßíáé ìåôáíÜóôåò/óôñéåò áðü ÷þñåò ìå ãåíéêåõìÝíç HIV ëïßìùîç 1
  • 55,7% äéáãíþóôçêáí óå ðñï÷ùñçìÝíï óôÜäéï ôçò íüóïõ ôï 2015 (ôï õøçëüôåñï ðïóïóôü óôç Ä. Åõñþðç) 1
  • 807 ïñïèåôéêÜ Üôïìá ðñïÝñ÷ïíôáé áðü ÷þñåò ìå ãåíéêåõìÝíç åðéäçìßá AIDS 1
  • 65 ìùñÜ ãåííÞèçêáí ìå HIV ëïßìùîç 1
  • 997 óôá 1000 Üôïìá äåí Ý÷ïõí êÜíåé ðïôÝ HIV test áðü ôï 2004 1

ÐçãÝò: European Centre for Disease Prevention and Control1, ÊÝíôñï ÅëÝã÷ïõ êáé Ðñüëçøçò ÍïóçìÜôùí2

Ôï ãåíåôéêü ðñïößë ôïõ HIV/AIDS óôçí ÅëëÜäá

Ç Ýñåõíá ðïõ áöïñÜ ôç ãåíåôéêÞ ðïéêéëïìïñößá ôïõ éïý HIV åßíáé éäéáéôÝñùò óçìáíôéêÞ ãéá ôç ìåëÝôç ôçò äõíáìéêÞò åîÜðëùóçò ôïõ éïý, áëëÜ êáé ãéá ôçí áíÜðôõîç íÝùí äéáãíùóôéêþí ìåèüäùí êáé åìâïëßùí. Óå ìåëÝôç 1147 áóèåíþí ôç ÷ñïíéêÞ ðåñßïäï 1999-2005 ç êáôáíïìÞ ôùí õðüôõðùí êáé áíáóõíäõáóìÝíùí ôýðùí ôïõ HIV-1 Þôáí:

  1. Õðüôõðïò B (n=756, 66%)
  2. Õðüôõðïò A (n=226, 20%)
  3. Õðüôõðïò C (n=49, 4%)
  4. Õðüôõðïò D, F, G, êáé H (n=31, 3%)

Ïé ìç- õðüôõðïé âñÝèçêáí óå ìåãáëýôåñç óõ÷íüôçôá óå ðáéäéÜ ðïõ ìïëýíèçêáí ìå êÜèåôç ìåôÜäïóç (63%), óå åôåñïöõëüöéëïõò (43%) êáé ÷ñÞóôåò åíäïöëÝâéùí íáñêùôéêþí (39%) óå ó÷Ýóç ìå ïìïöõëüöéëïõò (27%) êáé áéìïññïöéëéêïýò (0%). Ï åðéðïëáóìüò ôùí ìç- õðüôõðùí Þôáí óçìáíôéêÜ õøçëüôåñïò (56%) óå áóèåíåßò ìå íåïäéáãíùóèåßóá HIV-1 ëïßìùîç ìå çìåñïìçíßá äéÜãíùóçò ìåôáîý 2002 êáé 2005, óå ó÷Ýóç ìå ôïõò õðüëïéðïõò áóèåíåßò (29%) êáé åßíáé õøçëüôåñïò óôçí ÅëëÜäá óå ó÷Ýóç ìå Üëëåò ÌåóïãåéáêÝò ÷þñåò (Éôáëßá, Éóðáíßá) ðáñïõóéÜæïíôáò áõîçôéêÝò ôÜóåéò ôá ôåëåõôáßá ÷ñüíéá.
Ç åìöÜíéóç áíôï÷Þò óå áóèåíåßò ìå HIV ëïßìùîç áðïôåëåß Ýíá ðïëý óçìáíôéêü ðñüâëçìá äçìüóéáò õãåßáò. Óå áíôéðñïóùðåõôéêü äåßãìá áóèåíþí óôçí ÅëëÜäá ìå íåïäéáãíùóèåßóá HIV ëïßìùîç ïé ïðïßïé äåí Ý÷ïõí ëÜâåé èåñáðåßá, ï óõíïëéêüò åðéðïëáóìüò áíôï÷Þò åêôéìÞèçêå óôï 12% êáé óõíäÝåôáé ìå NRTIs, NNRTIs êáé PIs.
Ï åðéðïëáóìüò ìåôáëëáãþí ðïõ ðñïóäßäïõí áíôï÷Þ óå NRTIs Þôáí 8%, óå NNRTIs Þôáí 3%, êáé ï åðéðïëáóìüò ôùí êýñéùí ìåôáëëáãþí ðïõ óõíäÝïíôáé ìå áíôï÷Þ óå áíáóôïëåßò ðñùôåáóþí (PIs) Þôáí 4%.
Åðßóçò, óå 1% ôùí áóèåíþí âñÝèçêå áíôï÷Þ óå ðáñáðÜíù áðü 1 êáôçãïñßá öáñìÜêùí (ðïëõáíôï÷Þ). Ôá áðïôåëÝóìáôá áõôÜ åðéâåâáéþíïõí ôçí áíÜãêç åëÝã÷ïõ áíôï÷Þò ðñéí ôçí Ýíáñîç èåñáðåßáò.

Ïé ðñùôéÝò ôçò ÅëëÜäáò

Áðü ôçí Ýêèåóç ôïõ 2003 ôïõ Ðáãêüóìéïõ Ïñãáíéóìïý Õãåßáò ãéá ôçí Åõñþðç ðñïÝêõøáí ôá åîÞò, ðïëý åíäéáöÝñïíôá óôáôéóôéêÜ óôïé÷åßá ãéá ôçí ÅëëÜäá.

Table 6. HIV infections newly diagnosed in persons (100%) infected through heterosexual contact, by country and transmission subcategory, cases reported in 2002-2003,WHO European Region, data reported by 30 June 2003

* High risk sex partner: bisexual male, IDU, haemophiliac or transfusion recipient
Table 14. Systematic HIV antibody screening in blood banks: HIV prevalence in blood donations by country, WHO European Region

* Candidate donors: persons who apply for donating blood and have an initial HIV test before they can be registered as blood donors
Table 15. Systematic HIV antibody screening in blood banks: HIV prevalence in blood donations from new or candidate* donors by country, WHO European Region

* Candidate donors: persons who apply for donating blood and have an initial HIV test before they can be registered as blood donors

+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Another step towards closing the paediatric treatment gap

Expanding access to antiretroviral therapy (ART) and reducing new HIV acquisitions among women has led to a marked decline in vertical HIV transmission over the past decade. Nevertheless, in 2023 alone, an estimated 120 000 children aged 0–14 years acquired HIV globally, with the vast majority living in Africa.1 Without treatment, over half of infants and young children with perinatally acquired HIV die before their second birthday.2 Early diagnosis and timely linkage to care are therefore essential to reducing morbidity and mortality.

Deworming of filariasis and reduction of HIV incidence

In sub-Saharan Africa, lymphatic filariasis and HIV infection are two major public health problems that often coexist.1 For several decades, scientists have been exploring the negative impact of helminth infections, including the filarial nematode Wucheria bancrofti, on HIV acquisition and pathogenesis.1–3 Immunological studies have tried to validate the anecdotal, but biologically plausible, theory that modulatory effects of helminths such as W bancrofti can affect HIV infection.3–5 However, some of these studies were inconclusive, and many were characterised by two common flaws, cross-sectional design1 or small sample size,3 weakening the strength of the evidence.

Modelling study shows staggering impact of HIV funding cuts

The global AIDS response has seen substantial reductions in HIV incidence and number of deaths.1 The greatest improvements have been recorded in sub-Saharan Africa, the region with the worst HIV burden. Many of the advances are attributed to international funding of national programmes within sub-Saharan Africa. International contributions were estimated to be 41% of total HIV expenditure in low-income and middle-income countries (LMICs) in 2023.1 Over the last 5–10 years there have been reported declines in HIV funding from both domestic contributions and non-US international funders.

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò

ÔçëåöùíéêÞ ãñáììÞ ãéá ôï HIV/AIDS

210-7222222

ÄåõôÝñá - ÐáñáóêåõÞ
09:00 - 21:00